<DOC>
	<DOCNO>NCT00666458</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This study design assess efficacy tolerability saxagliptin addition metformin compare sitagliptin addition metformin .</brief_summary>
	<brief_title>18-week add-on Metformin Comparison Saxagliptin Sitagliptin Adult Patients With Type 2 Diabetes ( T2D )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosed type 2 diabetes Treatment metformin alone stable dos 1500 mg high per day least 8 week Type 1 diabetes , history diabetic ketoacidosis hyperosmolar nonketotic coma Insulin therapy within one year Previous treatment DPP4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metformin</keyword>
</DOC>